Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elaine Lopez

Nurse Practitioner, Family Orchard Park, NY Nurse Practitioner

NPI 1316225360 CMS profile 105317

3065 Southwestern Blvd, Ste 100, Orchard Park, NY 14127

Open in the dashboard

General payments

$10,303

633 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elaine Lopez of Orchard Park, NY is reported in the CMS Open Payments database as having received $10,303 across 633 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,676 149
2024 General $2,576 148
2023 General $2,438 149
2022 General $1,837 127
2021 General $776 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elaine Lopez
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Elaine Lopez were reported at $2,676. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Elaine Lopez Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $776 $124 $35–$379 $132
2022 $1,837 $141 $44–$430 $149
2023 $2,438 $154 $49–$476 $160
2024 $2,576 $165 $51–$504 $164
2025 $2,676 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,498 136 payments
  2. Pfizer Inc. $1,442 98 payments
  3. Janssen Biotech, Inc. $1,228 97 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,064 56 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,042 86 payments
  6. QOL Medical, LLC $783 48 payments
  7. Celgene Corporation $372 27 payments
  8. Regeneron Healthcare Solutions, Inc. $274 8 payments
  9. Ardelyx, Inc. $164 7 payments
  10. Intercept Pharmaceuticals, Inc. $156 7 payments
  11. Other $1,279 63 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,185 630 payments
  2. Education $119 3 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,064 88 payments
  2. RINVOQ $1,017 49 payments
  3. CREON $855 46 payments
  4. XELJANZ $788 59 payments
  5. LINZESS $784 42 payments
  6. STELARA $779 63 payments
  7. VELSIPITY $774 48 payments
  8. ENTYVIO $737 33 payments
  9. SKYRIZI Immunology $555 30 payments
  10. SKYRIZI Immunology $480 19 payments
  11. Other $4,991 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,845

Median for Nurse Practitioner: 389

Drug cost

$2,284,935

Median for Nurse Practitioner: $21,885

Branded share of claims

23.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 35 $955,013
Humira(Cf) Pen Adalimumab Brand 54 $646,761
Xeljanz Tofacitinib Citrate Brand 34 $203,057
Humira Pen Adalimumab Brand 12 $144,212
Creon Lipase/Protease/Amylase Brand 25 $74,362
Linzess Linaclotide Brand 60 $70,783
Mesalamine Generic 48 $26,691
Mounjaro Tirzepatide Brand 18 $18,202
Lubiprostone Generic 57 $17,228
Mesalamine Er Mesalamine Brand 28 $16,981

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$19,304

Medicare's payments for the services billed

Medicare patients

200

Average age 70

Services billed

333

118 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 55%
Chronic kidney disease 31%
Ischemic heart disease 28%
Diabetes 27%
Depression 26%
COPD 22%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VELSIPITY
$339 — —
Sucraid
$260 — —
RINVOQ
$255 — —
SKYRIZI
$205 — —
STELARA
$182 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

633 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record